Form 4: Veracyte Executive John Leite Sells Shares Under 10b5-1 Plan

John Leite, Chief Commercial Officer-CLIA of Veracyte, Inc., sold 5,479 shares of common stock on September 4, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On September 4, 2024, John Leite, the Chief Commercial Officer-CLIA of Veracyte, Inc. (VCYT), sold 5,479 shares of the company's common stock.
• The sale was executed at a weighted average price of $29.779 per share.
• The prices for individual transactions ranged from $29.24 to $30.24.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 1, 2024.
• Following the transaction, Leite directly owns 76,174 shares of Veracyte common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. The use of a 10b5-1 plan suggests the sale was pre-planned and not based on any inside information, resulting in a neutral sentiment.

Industry Context

Sales by company executives are a normal part of corporate governance. The use of a 10b5-1 plan suggests the sales were pre-planned and not based on any inside information.

Stakeholder Impact

• The sale of shares by an executive could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.

Key Dates